nodes	percent_of_prediction	percent_of_DWPC	metapath
Trametinib—CYP2C8—Paclitaxel—ovarian cancer	0.0442	0.302	CbGbCtD
Trametinib—CYP3A4—Topotecan—ovarian cancer	0.0362	0.247	CbGbCtD
Trametinib—CYP3A4—Vinorelbine—ovarian cancer	0.0255	0.174	CbGbCtD
Trametinib—CYP3A4—Paclitaxel—ovarian cancer	0.0179	0.122	CbGbCtD
Trametinib—CYP3A4—Docetaxel—ovarian cancer	0.013	0.0885	CbGbCtD
Trametinib—CYP3A4—Doxorubicin—ovarian cancer	0.00966	0.066	CbGbCtD
Trametinib—MAP2K1—embryo—ovarian cancer	0.00796	0.0811	CbGeAlD
Trametinib—MAP2K2—myometrium—ovarian cancer	0.00728	0.0743	CbGeAlD
Trametinib—MAP2K1—epithelium—ovarian cancer	0.00649	0.0662	CbGeAlD
Trametinib—MAP2K2—uterine cervix—ovarian cancer	0.00567	0.0578	CbGeAlD
Trametinib—MAP2K1—gonad—ovarian cancer	0.0054	0.0551	CbGeAlD
Trametinib—MAP2K2—decidua—ovarian cancer	0.0054	0.0551	CbGeAlD
Trametinib—MAP2K2—endometrium—ovarian cancer	0.00513	0.0523	CbGeAlD
Trametinib—MAP2K1—female reproductive system—ovarian cancer	0.00482	0.0492	CbGeAlD
Trametinib—MAP2K2—gonad—ovarian cancer	0.00475	0.0485	CbGeAlD
Trametinib—MAP2K2—uterus—ovarian cancer	0.00472	0.0482	CbGeAlD
Trametinib—MAP2K1—bone marrow—ovarian cancer	0.00455	0.0464	CbGeAlD
Trametinib—MAP2K1—female gonad—ovarian cancer	0.00439	0.0447	CbGeAlD
Trametinib—MAP2K2—female reproductive system—ovarian cancer	0.00425	0.0433	CbGeAlD
Trametinib—MAP2K2—bone marrow—ovarian cancer	0.00401	0.0409	CbGeAlD
Trametinib—MAP2K1—testis—ovarian cancer	0.00389	0.0397	CbGeAlD
Trametinib—MAP2K2—female gonad—ovarian cancer	0.00386	0.0394	CbGeAlD
Trametinib—MAP2K2—testis—ovarian cancer	0.00343	0.0349	CbGeAlD
Trametinib—MAP2K1—lymph node—ovarian cancer	0.00282	0.0288	CbGeAlD
Trametinib—MAP2K2—lymph node—ovarian cancer	0.00248	0.0253	CbGeAlD
Trametinib—CYP2C8—endometrium—ovarian cancer	0.00177	0.0181	CbGeAlD
Trametinib—CYP2C8—female reproductive system—ovarian cancer	0.00147	0.015	CbGeAlD
Trametinib—CYP2C8—vagina—ovarian cancer	0.00133	0.0136	CbGeAlD
Trametinib—CYP2C8—testis—ovarian cancer	0.00119	0.0121	CbGeAlD
Trametinib—CYP3A4—female reproductive system—ovarian cancer	0.000996	0.0102	CbGeAlD
Trametinib—Diarrhoea—Topotecan—ovarian cancer	0.000329	0.000996	CcSEcCtD
Trametinib—Cardiac failure congestive—Doxorubicin—ovarian cancer	0.000329	0.000995	CcSEcCtD
Trametinib—Back pain—Paclitaxel—ovarian cancer	0.000328	0.000993	CcSEcCtD
Trametinib—Urinary tract disorder—Docetaxel—ovarian cancer	0.000326	0.000987	CcSEcCtD
Trametinib—Muscle spasms—Paclitaxel—ovarian cancer	0.000326	0.000987	CcSEcCtD
Trametinib—Abdominal pain—Vinorelbine—ovarian cancer	0.000326	0.000985	CcSEcCtD
Trametinib—Body temperature increased—Vinorelbine—ovarian cancer	0.000326	0.000985	CcSEcCtD
Trametinib—Oedema peripheral—Docetaxel—ovarian cancer	0.000326	0.000985	CcSEcCtD
Trametinib—Connective tissue disorder—Docetaxel—ovarian cancer	0.000325	0.000982	CcSEcCtD
Trametinib—Urethral disorder—Docetaxel—ovarian cancer	0.000324	0.00098	CcSEcCtD
Trametinib—Hyponatraemia—Epirubicin—ovarian cancer	0.000323	0.000979	CcSEcCtD
Trametinib—Renal failure acute—Doxorubicin—ovarian cancer	0.000323	0.000977	CcSEcCtD
Trametinib—Diarrhoea—Melphalan—ovarian cancer	0.000322	0.000976	CcSEcCtD
Trametinib—Pain in extremity—Epirubicin—ovarian cancer	0.000322	0.000975	CcSEcCtD
Trametinib—Nausea—Chlorambucil—ovarian cancer	0.000321	0.000972	CcSEcCtD
Trametinib—Vision blurred—Paclitaxel—ovarian cancer	0.00032	0.000968	CcSEcCtD
Trametinib—Dizziness—Topotecan—ovarian cancer	0.000318	0.000963	CcSEcCtD
Trametinib—Anaemia—Paclitaxel—ovarian cancer	0.000314	0.000949	CcSEcCtD
Trametinib—Eye disorder—Docetaxel—ovarian cancer	0.000309	0.000934	CcSEcCtD
Trametinib—Cardiac disorder—Docetaxel—ovarian cancer	0.000307	0.000928	CcSEcCtD
Trametinib—Vomiting—Topotecan—ovarian cancer	0.000306	0.000926	CcSEcCtD
Trametinib—Leukopenia—Paclitaxel—ovarian cancer	0.000304	0.000919	CcSEcCtD
Trametinib—Rash—Topotecan—ovarian cancer	0.000304	0.000918	CcSEcCtD
Trametinib—Dermatitis—Topotecan—ovarian cancer	0.000303	0.000917	CcSEcCtD
Trametinib—Blood creatinine increased—Epirubicin—ovarian cancer	0.000302	0.000913	CcSEcCtD
Trametinib—Headache—Topotecan—ovarian cancer	0.000302	0.000912	CcSEcCtD
Trametinib—Angiopathy—Docetaxel—ovarian cancer	0.0003	0.000907	CcSEcCtD
Trametinib—Vomiting—Melphalan—ovarian cancer	0.0003	0.000907	CcSEcCtD
Trametinib—Dehydration—Epirubicin—ovarian cancer	0.0003	0.000906	CcSEcCtD
Trametinib—Hyponatraemia—Doxorubicin—ovarian cancer	0.000299	0.000906	CcSEcCtD
Trametinib—Pain in extremity—Doxorubicin—ovarian cancer	0.000298	0.000902	CcSEcCtD
Trametinib—Mediastinal disorder—Docetaxel—ovarian cancer	0.000298	0.000901	CcSEcCtD
Trametinib—Rash—Melphalan—ovarian cancer	0.000297	0.000899	CcSEcCtD
Trametinib—Dermatitis—Melphalan—ovarian cancer	0.000297	0.000898	CcSEcCtD
Trametinib—Chills—Docetaxel—ovarian cancer	0.000296	0.000897	CcSEcCtD
Trametinib—Cough—Paclitaxel—ovarian cancer	0.000296	0.000896	CcSEcCtD
Trametinib—Asthenia—Vinorelbine—ovarian cancer	0.000295	0.000894	CcSEcCtD
Trametinib—Dry skin—Epirubicin—ovarian cancer	0.000295	0.000893	CcSEcCtD
Trametinib—Arrhythmia—Docetaxel—ovarian cancer	0.000295	0.000893	CcSEcCtD
Trametinib—Abdominal pain upper—Epirubicin—ovarian cancer	0.000294	0.00089	CcSEcCtD
Trametinib—Hypokalaemia—Epirubicin—ovarian cancer	0.000293	0.000887	CcSEcCtD
Trametinib—Hypertension—Paclitaxel—ovarian cancer	0.000293	0.000886	CcSEcCtD
Trametinib—Pruritus—Vinorelbine—ovarian cancer	0.000291	0.000881	CcSEcCtD
Trametinib—Aspartate aminotransferase increased—Epirubicin—ovarian cancer	0.00029	0.000878	CcSEcCtD
Trametinib—Mental disorder—Docetaxel—ovarian cancer	0.00029	0.000876	CcSEcCtD
Trametinib—Myalgia—Paclitaxel—ovarian cancer	0.000289	0.000874	CcSEcCtD
Trametinib—Arthralgia—Paclitaxel—ovarian cancer	0.000289	0.000874	CcSEcCtD
Trametinib—Erythema—Docetaxel—ovarian cancer	0.000288	0.00087	CcSEcCtD
Trametinib—Malnutrition—Docetaxel—ovarian cancer	0.000288	0.00087	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000287	0.000868	CcSEcCtD
Trametinib—Nausea—Topotecan—ovarian cancer	0.000286	0.000865	CcSEcCtD
Trametinib—Alanine aminotransferase increased—Epirubicin—ovarian cancer	0.000284	0.00086	CcSEcCtD
Trametinib—Dry mouth—Paclitaxel—ovarian cancer	0.000283	0.000855	CcSEcCtD
Trametinib—Diarrhoea—Vinorelbine—ovarian cancer	0.000282	0.000852	CcSEcCtD
Trametinib—Dysgeusia—Docetaxel—ovarian cancer	0.000282	0.000852	CcSEcCtD
Trametinib—Nausea—Melphalan—ovarian cancer	0.00028	0.000847	CcSEcCtD
Trametinib—Blood creatinine increased—Doxorubicin—ovarian cancer	0.000279	0.000845	CcSEcCtD
Trametinib—Back pain—Docetaxel—ovarian cancer	0.000278	0.000842	CcSEcCtD
Trametinib—Dehydration—Doxorubicin—ovarian cancer	0.000277	0.000839	CcSEcCtD
Trametinib—Oedema—Paclitaxel—ovarian cancer	0.000277	0.000838	CcSEcCtD
Trametinib—Muscle spasms—Docetaxel—ovarian cancer	0.000277	0.000837	CcSEcCtD
Trametinib—Infection—Paclitaxel—ovarian cancer	0.000275	0.000833	CcSEcCtD
Trametinib—Dry skin—Doxorubicin—ovarian cancer	0.000273	0.000827	CcSEcCtD
Trametinib—Pancreatitis—Epirubicin—ovarian cancer	0.000273	0.000826	CcSEcCtD
Trametinib—Dizziness—Vinorelbine—ovarian cancer	0.000272	0.000824	CcSEcCtD
Trametinib—Abdominal pain upper—Doxorubicin—ovarian cancer	0.000272	0.000824	CcSEcCtD
Trametinib—Nervous system disorder—Paclitaxel—ovarian cancer	0.000272	0.000822	CcSEcCtD
Trametinib—Hypokalaemia—Doxorubicin—ovarian cancer	0.000271	0.000821	CcSEcCtD
Trametinib—Thrombocytopenia—Paclitaxel—ovarian cancer	0.000271	0.00082	CcSEcCtD
Trametinib—Skin disorder—Paclitaxel—ovarian cancer	0.000269	0.000814	CcSEcCtD
Trametinib—Aspartate aminotransferase increased—Doxorubicin—ovarian cancer	0.000268	0.000812	CcSEcCtD
Trametinib—Hyperhidrosis—Paclitaxel—ovarian cancer	0.000268	0.00081	CcSEcCtD
Trametinib—Anaemia—Docetaxel—ovarian cancer	0.000266	0.000804	CcSEcCtD
Trametinib—Alanine aminotransferase increased—Doxorubicin—ovarian cancer	0.000263	0.000795	CcSEcCtD
Trametinib—Vomiting—Vinorelbine—ovarian cancer	0.000262	0.000792	CcSEcCtD
Trametinib—Neutropenia—Epirubicin—ovarian cancer	0.00026	0.000788	CcSEcCtD
Trametinib—Rash—Vinorelbine—ovarian cancer	0.00026	0.000786	CcSEcCtD
Trametinib—Dermatitis—Vinorelbine—ovarian cancer	0.000259	0.000785	CcSEcCtD
Trametinib—Headache—Vinorelbine—ovarian cancer	0.000258	0.00078	CcSEcCtD
Trametinib—Leukopenia—Docetaxel—ovarian cancer	0.000257	0.000779	CcSEcCtD
Trametinib—Pancreatitis—Doxorubicin—ovarian cancer	0.000253	0.000764	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000252	0.000763	CcSEcCtD
Trametinib—Hyperglycaemia—Epirubicin—ovarian cancer	0.000251	0.00076	CcSEcCtD
Trametinib—Cough—Docetaxel—ovarian cancer	0.000251	0.000759	CcSEcCtD
Trametinib—Insomnia—Paclitaxel—ovarian cancer	0.000251	0.000758	CcSEcCtD
Trametinib—Hypertension—Docetaxel—ovarian cancer	0.000248	0.000751	CcSEcCtD
Trametinib—Infestation NOS—Epirubicin—ovarian cancer	0.000248	0.000751	CcSEcCtD
Trametinib—Infestation—Epirubicin—ovarian cancer	0.000248	0.000751	CcSEcCtD
Trametinib—Myalgia—Docetaxel—ovarian cancer	0.000245	0.000741	CcSEcCtD
Trametinib—Arthralgia—Docetaxel—ovarian cancer	0.000245	0.000741	CcSEcCtD
Trametinib—Nausea—Vinorelbine—ovarian cancer	0.000245	0.00074	CcSEcCtD
Trametinib—Renal failure—Epirubicin—ovarian cancer	0.000244	0.000738	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000243	0.000736	CcSEcCtD
Trametinib—Stomatitis—Epirubicin—ovarian cancer	0.000242	0.000732	CcSEcCtD
Trametinib—Urinary tract infection—Epirubicin—ovarian cancer	0.000241	0.00073	CcSEcCtD
Trametinib—Neutropenia—Doxorubicin—ovarian cancer	0.000241	0.000729	CcSEcCtD
Trametinib—Decreased appetite—Paclitaxel—ovarian cancer	0.000241	0.000728	CcSEcCtD
Trametinib—Dry mouth—Docetaxel—ovarian cancer	0.00024	0.000725	CcSEcCtD
Trametinib—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000239	0.000723	CcSEcCtD
Trametinib—Fatigue—Paclitaxel—ovarian cancer	0.000239	0.000722	CcSEcCtD
Trametinib—Constipation—Paclitaxel—ovarian cancer	0.000237	0.000717	CcSEcCtD
Trametinib—Haematuria—Epirubicin—ovarian cancer	0.000237	0.000716	CcSEcCtD
Trametinib—Oedema—Docetaxel—ovarian cancer	0.000235	0.00071	CcSEcCtD
Trametinib—Epistaxis—Epirubicin—ovarian cancer	0.000234	0.000709	CcSEcCtD
Trametinib—Infection—Docetaxel—ovarian cancer	0.000233	0.000706	CcSEcCtD
Trametinib—Hyperglycaemia—Doxorubicin—ovarian cancer	0.000232	0.000703	CcSEcCtD
Trametinib—Nervous system disorder—Docetaxel—ovarian cancer	0.00023	0.000697	CcSEcCtD
Trametinib—Thrombocytopenia—Docetaxel—ovarian cancer	0.00023	0.000695	CcSEcCtD
Trametinib—Infestation NOS—Doxorubicin—ovarian cancer	0.00023	0.000695	CcSEcCtD
Trametinib—Infestation—Doxorubicin—ovarian cancer	0.00023	0.000695	CcSEcCtD
Trametinib—Skin disorder—Docetaxel—ovarian cancer	0.000228	0.00069	CcSEcCtD
Trametinib—Bradycardia—Epirubicin—ovarian cancer	0.000227	0.000686	CcSEcCtD
Trametinib—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000226	0.000685	CcSEcCtD
Trametinib—Renal failure—Doxorubicin—ovarian cancer	0.000226	0.000683	CcSEcCtD
Trametinib—Haemoglobin—Epirubicin—ovarian cancer	0.000224	0.000678	CcSEcCtD
Trametinib—Stomatitis—Doxorubicin—ovarian cancer	0.000224	0.000677	CcSEcCtD
Trametinib—Urinary tract infection—Doxorubicin—ovarian cancer	0.000223	0.000676	CcSEcCtD
Trametinib—Haemorrhage—Epirubicin—ovarian cancer	0.000223	0.000674	CcSEcCtD
Trametinib—Urinary tract disorder—Epirubicin—ovarian cancer	0.00022	0.000666	CcSEcCtD
Trametinib—Oedema peripheral—Epirubicin—ovarian cancer	0.00022	0.000664	CcSEcCtD
Trametinib—Haematuria—Doxorubicin—ovarian cancer	0.000219	0.000663	CcSEcCtD
Trametinib—Connective tissue disorder—Epirubicin—ovarian cancer	0.000219	0.000663	CcSEcCtD
Trametinib—Abdominal pain—Paclitaxel—ovarian cancer	0.000219	0.000662	CcSEcCtD
Trametinib—Body temperature increased—Paclitaxel—ovarian cancer	0.000219	0.000662	CcSEcCtD
Trametinib—Urethral disorder—Epirubicin—ovarian cancer	0.000218	0.000661	CcSEcCtD
Trametinib—Epistaxis—Doxorubicin—ovarian cancer	0.000217	0.000656	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000214	0.000647	CcSEcCtD
Trametinib—Insomnia—Docetaxel—ovarian cancer	0.000212	0.000642	CcSEcCtD
Trametinib—Bradycardia—Doxorubicin—ovarian cancer	0.00021	0.000635	CcSEcCtD
Trametinib—Eye disorder—Epirubicin—ovarian cancer	0.000208	0.00063	CcSEcCtD
Trametinib—Haemoglobin—Doxorubicin—ovarian cancer	0.000207	0.000627	CcSEcCtD
Trametinib—Cardiac disorder—Epirubicin—ovarian cancer	0.000207	0.000626	CcSEcCtD
Trametinib—Haemorrhage—Doxorubicin—ovarian cancer	0.000206	0.000624	CcSEcCtD
Trametinib—Decreased appetite—Docetaxel—ovarian cancer	0.000204	0.000617	CcSEcCtD
Trametinib—Urinary tract disorder—Doxorubicin—ovarian cancer	0.000204	0.000616	CcSEcCtD
Trametinib—Oedema peripheral—Doxorubicin—ovarian cancer	0.000203	0.000615	CcSEcCtD
Trametinib—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000203	0.000613	CcSEcCtD
Trametinib—Connective tissue disorder—Doxorubicin—ovarian cancer	0.000203	0.000613	CcSEcCtD
Trametinib—Fatigue—Docetaxel—ovarian cancer	0.000202	0.000612	CcSEcCtD
Trametinib—Angiopathy—Epirubicin—ovarian cancer	0.000202	0.000612	CcSEcCtD
Trametinib—Urethral disorder—Doxorubicin—ovarian cancer	0.000202	0.000612	CcSEcCtD
Trametinib—Mediastinal disorder—Epirubicin—ovarian cancer	0.000201	0.000608	CcSEcCtD
Trametinib—Constipation—Docetaxel—ovarian cancer	0.000201	0.000607	CcSEcCtD
Trametinib—Chills—Epirubicin—ovarian cancer	0.0002	0.000605	CcSEcCtD
Trametinib—Arrhythmia—Epirubicin—ovarian cancer	0.000199	0.000602	CcSEcCtD
Trametinib—Asthenia—Paclitaxel—ovarian cancer	0.000199	0.000601	CcSEcCtD
Trametinib—Pruritus—Paclitaxel—ovarian cancer	0.000196	0.000593	CcSEcCtD
Trametinib—Mental disorder—Epirubicin—ovarian cancer	0.000195	0.000591	CcSEcCtD
Trametinib—Erythema—Epirubicin—ovarian cancer	0.000194	0.000587	CcSEcCtD
Trametinib—Malnutrition—Epirubicin—ovarian cancer	0.000194	0.000587	CcSEcCtD
Trametinib—Eye disorder—Doxorubicin—ovarian cancer	0.000193	0.000583	CcSEcCtD
Trametinib—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000192	0.000581	CcSEcCtD
Trametinib—Cardiac disorder—Doxorubicin—ovarian cancer	0.000191	0.000579	CcSEcCtD
Trametinib—Dysgeusia—Epirubicin—ovarian cancer	0.00019	0.000575	CcSEcCtD
Trametinib—Diarrhoea—Paclitaxel—ovarian cancer	0.00019	0.000573	CcSEcCtD
Trametinib—Back pain—Epirubicin—ovarian cancer	0.000188	0.000568	CcSEcCtD
Trametinib—Angiopathy—Doxorubicin—ovarian cancer	0.000187	0.000566	CcSEcCtD
Trametinib—Muscle spasms—Epirubicin—ovarian cancer	0.000187	0.000564	CcSEcCtD
Trametinib—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000186	0.000562	CcSEcCtD
Trametinib—Abdominal pain—Docetaxel—ovarian cancer	0.000186	0.000561	CcSEcCtD
Trametinib—Body temperature increased—Docetaxel—ovarian cancer	0.000186	0.000561	CcSEcCtD
Trametinib—Chills—Doxorubicin—ovarian cancer	0.000185	0.00056	CcSEcCtD
Trametinib—Arrhythmia—Doxorubicin—ovarian cancer	0.000184	0.000557	CcSEcCtD
Trametinib—Dizziness—Paclitaxel—ovarian cancer	0.000183	0.000554	CcSEcCtD
Trametinib—Vision blurred—Epirubicin—ovarian cancer	0.000183	0.000553	CcSEcCtD
Trametinib—Mental disorder—Doxorubicin—ovarian cancer	0.000181	0.000547	CcSEcCtD
Trametinib—Erythema—Doxorubicin—ovarian cancer	0.00018	0.000543	CcSEcCtD
Trametinib—Malnutrition—Doxorubicin—ovarian cancer	0.00018	0.000543	CcSEcCtD
Trametinib—Anaemia—Epirubicin—ovarian cancer	0.000179	0.000543	CcSEcCtD
Trametinib—Vomiting—Paclitaxel—ovarian cancer	0.000176	0.000533	CcSEcCtD
Trametinib—Dysgeusia—Doxorubicin—ovarian cancer	0.000176	0.000532	CcSEcCtD
Trametinib—Rash—Paclitaxel—ovarian cancer	0.000175	0.000528	CcSEcCtD
Trametinib—Dermatitis—Paclitaxel—ovarian cancer	0.000174	0.000528	CcSEcCtD
Trametinib—Leukopenia—Epirubicin—ovarian cancer	0.000174	0.000525	CcSEcCtD
Trametinib—Back pain—Doxorubicin—ovarian cancer	0.000174	0.000525	CcSEcCtD
Trametinib—Headache—Paclitaxel—ovarian cancer	0.000174	0.000525	CcSEcCtD
Trametinib—Muscle spasms—Doxorubicin—ovarian cancer	0.000173	0.000522	CcSEcCtD
Trametinib—Cough—Epirubicin—ovarian cancer	0.000169	0.000512	CcSEcCtD
Trametinib—Vision blurred—Doxorubicin—ovarian cancer	0.000169	0.000512	CcSEcCtD
Trametinib—Asthenia—Docetaxel—ovarian cancer	0.000168	0.00051	CcSEcCtD
Trametinib—Hypertension—Epirubicin—ovarian cancer	0.000168	0.000507	CcSEcCtD
Trametinib—Pruritus—Docetaxel—ovarian cancer	0.000166	0.000503	CcSEcCtD
Trametinib—Anaemia—Doxorubicin—ovarian cancer	0.000166	0.000502	CcSEcCtD
Trametinib—Myalgia—Epirubicin—ovarian cancer	0.000165	0.0005	CcSEcCtD
Trametinib—Arthralgia—Epirubicin—ovarian cancer	0.000165	0.0005	CcSEcCtD
Trametinib—Nausea—Paclitaxel—ovarian cancer	0.000165	0.000498	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000164	0.000496	CcSEcCtD
Trametinib—Dry mouth—Epirubicin—ovarian cancer	0.000162	0.000489	CcSEcCtD
Trametinib—Leukopenia—Doxorubicin—ovarian cancer	0.000161	0.000486	CcSEcCtD
Trametinib—Diarrhoea—Docetaxel—ovarian cancer	0.000161	0.000486	CcSEcCtD
Trametinib—Oedema—Epirubicin—ovarian cancer	0.000158	0.000479	CcSEcCtD
Trametinib—Infection—Epirubicin—ovarian cancer	0.000157	0.000476	CcSEcCtD
Trametinib—Cough—Doxorubicin—ovarian cancer	0.000157	0.000474	CcSEcCtD
Trametinib—Nervous system disorder—Epirubicin—ovarian cancer	0.000155	0.00047	CcSEcCtD
Trametinib—Dizziness—Docetaxel—ovarian cancer	0.000155	0.00047	CcSEcCtD
Trametinib—Thrombocytopenia—Epirubicin—ovarian cancer	0.000155	0.000469	CcSEcCtD
Trametinib—Hypertension—Doxorubicin—ovarian cancer	0.000155	0.000469	CcSEcCtD
Trametinib—Skin disorder—Epirubicin—ovarian cancer	0.000154	0.000465	CcSEcCtD
Trametinib—Hyperhidrosis—Epirubicin—ovarian cancer	0.000153	0.000463	CcSEcCtD
Trametinib—Arthralgia—Doxorubicin—ovarian cancer	0.000153	0.000462	CcSEcCtD
Trametinib—Myalgia—Doxorubicin—ovarian cancer	0.000153	0.000462	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000152	0.000459	CcSEcCtD
Trametinib—Dry mouth—Doxorubicin—ovarian cancer	0.000149	0.000452	CcSEcCtD
Trametinib—Vomiting—Docetaxel—ovarian cancer	0.000149	0.000452	CcSEcCtD
Trametinib—Rash—Docetaxel—ovarian cancer	0.000148	0.000448	CcSEcCtD
Trametinib—Dermatitis—Docetaxel—ovarian cancer	0.000148	0.000447	CcSEcCtD
Trametinib—Headache—Docetaxel—ovarian cancer	0.000147	0.000445	CcSEcCtD
Trametinib—Oedema—Doxorubicin—ovarian cancer	0.000147	0.000443	CcSEcCtD
Trametinib—Infection—Doxorubicin—ovarian cancer	0.000146	0.00044	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000144	0.000436	CcSEcCtD
Trametinib—Nervous system disorder—Doxorubicin—ovarian cancer	0.000144	0.000435	CcSEcCtD
Trametinib—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000143	0.000434	CcSEcCtD
Trametinib—Insomnia—Epirubicin—ovarian cancer	0.000143	0.000433	CcSEcCtD
Trametinib—Skin disorder—Doxorubicin—ovarian cancer	0.000142	0.000431	CcSEcCtD
Trametinib—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000142	0.000429	CcSEcCtD
Trametinib—Nausea—Docetaxel—ovarian cancer	0.000139	0.000422	CcSEcCtD
Trametinib—Decreased appetite—Epirubicin—ovarian cancer	0.000138	0.000416	CcSEcCtD
Trametinib—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000137	0.000414	CcSEcCtD
Trametinib—Fatigue—Epirubicin—ovarian cancer	0.000137	0.000413	CcSEcCtD
Trametinib—Constipation—Epirubicin—ovarian cancer	0.000135	0.00041	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000133	0.000404	CcSEcCtD
Trametinib—Insomnia—Doxorubicin—ovarian cancer	0.000133	0.000401	CcSEcCtD
Trametinib—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000129	0.000392	CcSEcCtD
Trametinib—Decreased appetite—Doxorubicin—ovarian cancer	0.000127	0.000385	CcSEcCtD
Trametinib—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000126	0.000383	CcSEcCtD
Trametinib—Fatigue—Doxorubicin—ovarian cancer	0.000126	0.000382	CcSEcCtD
Trametinib—Constipation—Doxorubicin—ovarian cancer	0.000125	0.000379	CcSEcCtD
Trametinib—Body temperature increased—Epirubicin—ovarian cancer	0.000125	0.000379	CcSEcCtD
Trametinib—Abdominal pain—Epirubicin—ovarian cancer	0.000125	0.000379	CcSEcCtD
Trametinib—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.00012	0.000362	CcSEcCtD
Trametinib—Body temperature increased—Doxorubicin—ovarian cancer	0.000116	0.00035	CcSEcCtD
Trametinib—Abdominal pain—Doxorubicin—ovarian cancer	0.000116	0.00035	CcSEcCtD
Trametinib—Asthenia—Epirubicin—ovarian cancer	0.000114	0.000344	CcSEcCtD
Trametinib—Pruritus—Epirubicin—ovarian cancer	0.000112	0.000339	CcSEcCtD
Trametinib—Diarrhoea—Epirubicin—ovarian cancer	0.000108	0.000328	CcSEcCtD
Trametinib—Asthenia—Doxorubicin—ovarian cancer	0.000105	0.000318	CcSEcCtD
Trametinib—Dizziness—Epirubicin—ovarian cancer	0.000105	0.000317	CcSEcCtD
Trametinib—Pruritus—Doxorubicin—ovarian cancer	0.000104	0.000314	CcSEcCtD
Trametinib—Vomiting—Epirubicin—ovarian cancer	0.000101	0.000305	CcSEcCtD
Trametinib—Diarrhoea—Doxorubicin—ovarian cancer	0.0001	0.000303	CcSEcCtD
Trametinib—Rash—Epirubicin—ovarian cancer	9.98e-05	0.000302	CcSEcCtD
Trametinib—Dermatitis—Epirubicin—ovarian cancer	9.98e-05	0.000302	CcSEcCtD
Trametinib—Headache—Epirubicin—ovarian cancer	9.92e-05	0.0003	CcSEcCtD
Trametinib—Dizziness—Doxorubicin—ovarian cancer	9.69e-05	0.000293	CcSEcCtD
Trametinib—Nausea—Epirubicin—ovarian cancer	9.41e-05	0.000285	CcSEcCtD
Trametinib—Vomiting—Doxorubicin—ovarian cancer	9.32e-05	0.000282	CcSEcCtD
Trametinib—Rash—Doxorubicin—ovarian cancer	9.24e-05	0.000279	CcSEcCtD
Trametinib—Dermatitis—Doxorubicin—ovarian cancer	9.23e-05	0.000279	CcSEcCtD
Trametinib—Headache—Doxorubicin—ovarian cancer	9.18e-05	0.000278	CcSEcCtD
Trametinib—Nausea—Doxorubicin—ovarian cancer	8.7e-05	0.000263	CcSEcCtD
Trametinib—MAP2K1—Signaling by NGF—AKT1—ovarian cancer	2.63e-05	6.18e-05	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—NRAS—ovarian cancer	2.62e-05	6.18e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—IL6ST—ovarian cancer	2.6e-05	6.13e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—PTEN—ovarian cancer	2.6e-05	6.12e-05	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—IL6—ovarian cancer	2.58e-05	6.06e-05	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—MAPK1—ovarian cancer	2.56e-05	6.02e-05	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—EGFR—ovarian cancer	2.56e-05	6.02e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—IL6ST—ovarian cancer	2.54e-05	5.98e-05	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—MAPK3—ovarian cancer	2.51e-05	5.92e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—TERT—ovarian cancer	2.5e-05	5.89e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—PIK3CG—ovarian cancer	2.5e-05	5.89e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—TLR4—ovarian cancer	2.48e-05	5.84e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—NRAS—ovarian cancer	2.48e-05	5.83e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CAV1—ovarian cancer	2.48e-05	5.83e-05	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—KRAS—ovarian cancer	2.41e-05	5.68e-05	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—MAPK1—ovarian cancer	2.39e-05	5.63e-05	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—EGFR—ovarian cancer	2.39e-05	5.63e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IL6ST—ovarian cancer	2.38e-05	5.6e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—MAPK3—ovarian cancer	2.37e-05	5.58e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PPP2R1A—ovarian cancer	2.36e-05	5.55e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—PIK3CD—ovarian cancer	2.35e-05	5.53e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—IL6ST—ovarian cancer	2.35e-05	5.52e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—NRAS—ovarian cancer	2.32e-05	5.46e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CAV1—ovarian cancer	2.32e-05	5.45e-05	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—KRAS—ovarian cancer	2.26e-05	5.32e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—MAPK1—ovarian cancer	2.26e-05	5.31e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—EGFR—ovarian cancer	2.26e-05	5.31e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—APC—ovarian cancer	2.26e-05	5.31e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CDH1—ovarian cancer	2.25e-05	5.29e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—MAPK3—ovarian cancer	2.22e-05	5.22e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PPP2R1A—ovarian cancer	2.21e-05	5.2e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—PIK3CD—ovarian cancer	2.2e-05	5.18e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—IL6ST—ovarian cancer	2.2e-05	5.17e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	2.19e-05	5.16e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—PIK3CD—ovarian cancer	2.15e-05	5.05e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—KRAS—ovarian cancer	2.13e-05	5.02e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—MAPK1—ovarian cancer	2.11e-05	4.97e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—EGFR—ovarian cancer	2.11e-05	4.97e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—APC—ovarian cancer	2.11e-05	4.97e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CDH1—ovarian cancer	2.1e-05	4.95e-05	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—HRAS—ovarian cancer	2.05e-05	4.83e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—PIK3CB—ovarian cancer	2.05e-05	4.82e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—YAP1—ovarian cancer	2.02e-05	4.75e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—PIK3CD—ovarian cancer	2.01e-05	4.73e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	2e-05	4.7e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—KRAS—ovarian cancer	2e-05	4.7e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PIK3CD—ovarian cancer	1.98e-05	4.67e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—CXCL8—ovarian cancer	1.97e-05	4.63e-05	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—IL6—ovarian cancer	1.96e-05	4.62e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—PIK3CA—ovarian cancer	1.96e-05	4.61e-05	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—HRAS—ovarian cancer	1.92e-05	4.52e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—PIK3CB—ovarian cancer	1.92e-05	4.51e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—ERBB2—ovarian cancer	1.9e-05	4.46e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—IL2—ovarian cancer	1.88e-05	4.43e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TERT—ovarian cancer	1.87e-05	4.41e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—PIK3CB—ovarian cancer	1.87e-05	4.41e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—MTOR—ovarian cancer	1.87e-05	4.41e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PIK3CD—ovarian cancer	1.85e-05	4.37e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CYTB—ovarian cancer	1.85e-05	4.35e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—CXCL8—ovarian cancer	1.84e-05	4.34e-05	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—IL6—ovarian cancer	1.84e-05	4.33e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—PIK3CA—ovarian cancer	1.83e-05	4.31e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—HRAS—ovarian cancer	1.81e-05	4.27e-05	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—AKT1—ovarian cancer	1.81e-05	4.27e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—ERBB2—ovarian cancer	1.77e-05	4.18e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—IL2—ovarian cancer	1.76e-05	4.14e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CDKN1B—ovarian cancer	1.76e-05	4.13e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.76e-05	4.13e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TERT—ovarian cancer	1.75e-05	4.13e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—MTOR—ovarian cancer	1.75e-05	4.12e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—PIK3CB—ovarian cancer	1.75e-05	4.12e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—ERBB2—ovarian cancer	1.75e-05	4.12e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—IL6—ovarian cancer	1.73e-05	4.08e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CAV1—ovarian cancer	1.73e-05	4.08e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PIK3CB—ovarian cancer	1.73e-05	4.07e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—MTOR—ovarian cancer	1.73e-05	4.07e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—IL2—ovarian cancer	1.72e-05	4.05e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—HRAS—ovarian cancer	1.7e-05	3.99e-05	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—AKT1—ovarian cancer	1.7e-05	3.99e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—ESR1—ovarian cancer	1.67e-05	3.93e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CTNNB1—ovarian cancer	1.66e-05	3.91e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—FASN—ovarian cancer	1.64e-05	3.87e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IL6ST—ovarian cancer	1.64e-05	3.87e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CDKN1B—ovarian cancer	1.64e-05	3.87e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—ERBB2—ovarian cancer	1.64e-05	3.86e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—IL6—ovarian cancer	1.62e-05	3.82e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CAV1—ovarian cancer	1.62e-05	3.82e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CDKN1B—ovarian cancer	1.62e-05	3.82e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—SLC5A5—ovarian cancer	1.62e-05	3.81e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—PTEN—ovarian cancer	1.62e-05	3.81e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PIK3CB—ovarian cancer	1.62e-05	3.81e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—MTOR—ovarian cancer	1.62e-05	3.81e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—BRIP1—ovarian cancer	1.61e-05	3.8e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PPP1CC—ovarian cancer	1.61e-05	3.8e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IL2—ovarian cancer	1.61e-05	3.79e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—AKT1—ovarian cancer	1.6e-05	3.77e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—APC—ovarian cancer	1.58e-05	3.72e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PIK3CG—ovarian cancer	1.58e-05	3.72e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—NRAS—ovarian cancer	1.58e-05	3.72e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—ESR1—ovarian cancer	1.56e-05	3.68e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—SLC2A1—ovarian cancer	1.56e-05	3.68e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CTNNB1—ovarian cancer	1.55e-05	3.65e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IL6ST—ovarian cancer	1.54e-05	3.62e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CTNNB1—ovarian cancer	1.53e-05	3.61e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.53e-05	3.6e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CDKN1B—ovarian cancer	1.52e-05	3.57e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—PTEN—ovarian cancer	1.51e-05	3.56e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—MAPK3—ovarian cancer	1.51e-05	3.56e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CYP1B1—ovarian cancer	1.5e-05	3.53e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—AKT1—ovarian cancer	1.5e-05	3.52e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PTEN—ovarian cancer	1.49e-05	3.51e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PIK3CG—ovarian cancer	1.48e-05	3.48e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—APC—ovarian cancer	1.48e-05	3.48e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—NRAS—ovarian cancer	1.48e-05	3.48e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—STAT3—ovarian cancer	1.45e-05	3.4e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—NRAS—ovarian cancer	1.44e-05	3.4e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—MAPK1—ovarian cancer	1.44e-05	3.39e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—EGFR—ovarian cancer	1.44e-05	3.39e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CTNNB1—ovarian cancer	1.43e-05	3.37e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—MAPK3—ovarian cancer	1.42e-05	3.33e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PTEN—ovarian cancer	1.4e-05	3.29e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PIK3CD—ovarian cancer	1.39e-05	3.27e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—MAPK3—ovarian cancer	1.38e-05	3.25e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—KRAS—ovarian cancer	1.36e-05	3.2e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—STAT3—ovarian cancer	1.35e-05	3.19e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—NRAS—ovarian cancer	1.35e-05	3.18e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—MAPK1—ovarian cancer	1.35e-05	3.17e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—EGFR—ovarian cancer	1.35e-05	3.17e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—STAT3—ovarian cancer	1.34e-05	3.14e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—NRAS—ovarian cancer	1.33e-05	3.14e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PPP2R1A—ovarian cancer	1.33e-05	3.13e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.32e-05	3.11e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—MAPK1—ovarian cancer	1.31e-05	3.09e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—EGFR—ovarian cancer	1.31e-05	3.09e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PIK3CD—ovarian cancer	1.3e-05	3.06e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—MAPK3—ovarian cancer	1.29e-05	3.04e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—MAPK3—ovarian cancer	1.28e-05	3e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—KRAS—ovarian cancer	1.27e-05	2.99e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—STAT3—ovarian cancer	1.25e-05	2.94e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—PIK3CA—ovarian cancer	1.25e-05	2.94e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—NRAS—ovarian cancer	1.25e-05	2.93e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—KRAS—ovarian cancer	1.24e-05	2.92e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—MYC—ovarian cancer	1.24e-05	2.92e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—ABCB1—ovarian cancer	1.23e-05	2.9e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—MAPK1—ovarian cancer	1.23e-05	2.9e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—EGFR—ovarian cancer	1.23e-05	2.9e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—ERBB2—ovarian cancer	1.23e-05	2.89e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—MAPK1—ovarian cancer	1.21e-05	2.86e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—EGFR—ovarian cancer	1.21e-05	2.86e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—TYMS—ovarian cancer	1.21e-05	2.85e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MTOR—ovarian cancer	1.21e-05	2.85e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PIK3CB—ovarian cancer	1.21e-05	2.85e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—MAPK3—ovarian cancer	1.19e-05	2.81e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—PIK3CA—ovarian cancer	1.17e-05	2.75e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CXCL8—ovarian cancer	1.16e-05	2.74e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—KRAS—ovarian cancer	1.16e-05	2.73e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—MYC—ovarian cancer	1.16e-05	2.73e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—HRAS—ovarian cancer	1.16e-05	2.72e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—ERBB2—ovarian cancer	1.15e-05	2.7e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—KRAS—ovarian cancer	1.15e-05	2.7e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—PIK3CA—ovarian cancer	1.14e-05	2.69e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—MAPK1—ovarian cancer	1.14e-05	2.67e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CDKN1B—ovarian cancer	1.14e-05	2.67e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—EGFR—ovarian cancer	1.14e-05	2.67e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MTOR—ovarian cancer	1.13e-05	2.66e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PIK3CB—ovarian cancer	1.13e-05	2.66e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CASP3—ovarian cancer	1.11e-05	2.62e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IL2—ovarian cancer	1.11e-05	2.62e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—IL6—ovarian cancer	1.11e-05	2.6e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CXCL8—ovarian cancer	1.09e-05	2.56e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CCND1—ovarian cancer	1.08e-05	2.55e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—YAP1—ovarian cancer	1.08e-05	2.55e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—HRAS—ovarian cancer	1.08e-05	2.54e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CTNNB1—ovarian cancer	1.07e-05	2.53e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—KRAS—ovarian cancer	1.07e-05	2.53e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—PIK3CA—ovarian cancer	1.07e-05	2.51e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CDKN1B—ovarian cancer	1.06e-05	2.5e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—HRAS—ovarian cancer	1.06e-05	2.48e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PIK3CA—ovarian cancer	1.05e-05	2.48e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MMP9—ovarian cancer	1.05e-05	2.48e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PTEN—ovarian cancer	1.05e-05	2.46e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CASP3—ovarian cancer	1.04e-05	2.45e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IL2—ovarian cancer	1.04e-05	2.45e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—IL6—ovarian cancer	1.03e-05	2.44e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—AKT1—ovarian cancer	1.02e-05	2.4e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CCND1—ovarian cancer	1.01e-05	2.39e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—IL6—ovarian cancer	1.01e-05	2.38e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CTNNB1—ovarian cancer	1e-05	2.36e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—HRAS—ovarian cancer	9.88e-06	2.32e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PIK3CA—ovarian cancer	9.86e-06	2.32e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MMP9—ovarian cancer	9.84e-06	2.32e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PTEN—ovarian cancer	9.78e-06	2.3e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CAV1—ovarian cancer	9.76e-06	2.3e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—HRAS—ovarian cancer	9.75e-06	2.29e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—AKT1—ovarian cancer	9.54e-06	2.25e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IL6—ovarian cancer	9.45e-06	2.22e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—VEGFA—ovarian cancer	9.45e-06	2.22e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—STAT3—ovarian cancer	9.35e-06	2.2e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—NRAS—ovarian cancer	9.33e-06	2.2e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—IL6—ovarian cancer	9.33e-06	2.2e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	9.33e-06	2.2e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—AKT1—ovarian cancer	9.32e-06	2.19e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—HRAS—ovarian cancer	9.12e-06	2.15e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MAPK3—ovarian cancer	8.94e-06	2.1e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PIK3CG—ovarian cancer	8.89e-06	2.09e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—VEGFA—ovarian cancer	8.84e-06	2.08e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—FASN—ovarian cancer	8.83e-06	2.08e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—STAT3—ovarian cancer	8.75e-06	2.06e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—NRAS—ovarian cancer	8.73e-06	2.05e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—IL6—ovarian cancer	8.73e-06	2.05e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—AKT1—ovarian cancer	8.72e-06	2.05e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MYC—ovarian cancer	8.69e-06	2.05e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—SLC5A5—ovarian cancer	8.68e-06	2.04e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—AKT1—ovarian cancer	8.61e-06	2.03e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MAPK1—ovarian cancer	8.5e-06	2e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—EGFR—ovarian cancer	8.5e-06	2e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—SLC2A1—ovarian cancer	8.39e-06	1.97e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MAPK3—ovarian cancer	8.36e-06	1.97e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MYC—ovarian cancer	8.13e-06	1.91e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—AKT1—ovarian cancer	8.05e-06	1.9e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CYP1B1—ovarian cancer	8.04e-06	1.89e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—KRAS—ovarian cancer	8.03e-06	1.89e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MAPK1—ovarian cancer	7.95e-06	1.87e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—EGFR—ovarian cancer	7.95e-06	1.87e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PIK3CD—ovarian cancer	7.82e-06	1.84e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—KRAS—ovarian cancer	7.51e-06	1.77e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PIK3CA—ovarian cancer	7.38e-06	1.74e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TP53—ovarian cancer	7.14e-06	1.68e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	7.13e-06	1.68e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PIK3CA—ovarian cancer	6.9e-06	1.62e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—HRAS—ovarian cancer	6.83e-06	1.61e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PIK3CB—ovarian cancer	6.81e-06	1.6e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TP53—ovarian cancer	6.68e-06	1.57e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ABCB1—ovarian cancer	6.62e-06	1.56e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IL6—ovarian cancer	6.53e-06	1.54e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—TYMS—ovarian cancer	6.5e-06	1.53e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—HRAS—ovarian cancer	6.39e-06	1.5e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IL6—ovarian cancer	6.11e-06	1.44e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—AKT1—ovarian cancer	6.03e-06	1.42e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PTEN—ovarian cancer	5.89e-06	1.39e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—AKT1—ovarian cancer	5.64e-06	1.33e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CAV1—ovarian cancer	5.24e-06	1.23e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PIK3CG—ovarian cancer	4.77e-06	1.12e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PIK3CD—ovarian cancer	4.2e-06	9.88e-06	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PIK3CA—ovarian cancer	4.15e-06	9.78e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PIK3CB—ovarian cancer	3.66e-06	8.61e-06	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—AKT1—ovarian cancer	3.39e-06	7.99e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PTEN—ovarian cancer	3.16e-06	7.44e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PIK3CA—ovarian cancer	2.23e-06	5.25e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—AKT1—ovarian cancer	1.82e-06	4.29e-06	CbGpPWpGaD
